<DOC>
	<DOCNO>NCT02418312</DOCNO>
	<brief_summary>Whether H2 receptor antagonist prevent thienopyridine-related peptic ulcer remain unclear .</brief_summary>
	<brief_title>Efficacy H2 Receptor Antagonist Prevention Thienopyridine-related Peptic Ulcer</brief_title>
	<detailed_description>The aim prospective , randomize study investigate efficacy H2 receptor antagonist prevention thienopyridine-related peptic ulcer gastrointestinal bleeding patient ulcer history . We plan enroll 236 thienopyridine ( clopidogrel ticlopidine ) user peptic ulcer history n't baseline gastroduodenal ulcer initial endoscopy . The patient randomly assign receive either ( 1 ) famotidine ( 40 mg qd ) plus thienopyridine use previously ( 2 ) placebo plus thienopyridine treatment alone 6 month . The ulcer recurrence rate treatment gruops compare .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Histamine H2 Antagonists</mesh_term>
	<criteria>1 . The past history gastroduodenal ulcer underwent endoscopy dyspeptic symptom . 2. thienopyridine user without baseline gastroduodenal ulcer initial endoscopy . 3 . They adult patient age least 20 year age . 1 . They history gastric duodenal surgery oversew perforation . 2 . They require longterm treatment nonsteroidal antiinflammatory drug . 3. serious disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>histamine-2 receptor antagonist</keyword>
	<keyword>peptic ulcer</keyword>
	<keyword>thienopyridine</keyword>
	<keyword>prevention</keyword>
</DOC>